GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (HKSE:09960) » Definitions » Capex-to-Operating-Cash-Flow

Kindstar Globalgene Technology (HKSE:09960) Capex-to-Operating-Cash-Flow : 1.00 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Kindstar Globalgene Technology's Capital Expenditure for the six months ended in Dec. 2024 was HK$-27.84 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2024 was HK$27.90 Mil.

Hence, Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2024 was 1.00.


Kindstar Globalgene Technology Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology Capex-to-Operating-Cash-Flow Chart

Kindstar Globalgene Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial 0.37 4.24 5.81 - -

Kindstar Globalgene Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 - - - 1.00

Competitive Comparison of Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow

For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow falls into.


;
;

Kindstar Globalgene Technology Capex-to-Operating-Cash-Flow Calculation

Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-144.623) / -47.105
=N/A

Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-27.843) / 27.899
=1.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kindstar Globalgene Technology  (HKSE:09960) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Kindstar Globalgene Technology Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Kindstar Globalgene Technology Business Description

Traded in Other Exchanges
N/A
Address
Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN
Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services in China. It organizes the business into the following segments; hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, scientific research services and CRO, and other segments provide testing services for R&D projects and others and miscellaneous services.
Executives
Mialkos Tomasz Jakub 2101 Beneficial owner
Orbimed Asia Partners Iv, L.p. 2101 Beneficial owner
Orbimed Asia Gp Iv, L.p. 2201 Interest of corporation controlled by you
Orbimed Advisors Iv Limited 2201 Interest of corporation controlled by you
Cpe Holdings International Limited 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p. 2201 Interest of corporation controlled by you
Cpe Holdings Limited 2201 Interest of corporation controlled by you
Cpe Funds Iii Limited 2201 Interest of corporation controlled by you
Ck Lab Tech Investment Limited 2101 Beneficial owner
Huang Bo
Jackson Hole Trust Company
Huang Shiang 2101 Beneficial owner
Ningbo Meishan Bonded Port Zone Ruifu Bojian Investment Management Co., Ltd.
Huang Zuie-chin 2101 Beneficial owner
Tu Zanbing

Kindstar Globalgene Technology Headlines

No Headlines